885518-82-1

Basic information

• Product Name: 1H-INDAZOLE-6-CARBOXYLIC ACID,3-IODO-,METHYL ESTER
• Synonyms: 1H-INDAZOLE-6-CARBOXYLIC ACID,3-IODO-,METHYL ESTER;Methyl 3-iodo-1H-indazole-6-carboxylate;Methyl 3-iodoindazole-6-carboxylate;3-Iodo-1H-indazole-6-carboxylic acid methyl ester;Methyl 3-iodoindazole-6-c...;3-iodo-6-methoxycarbonyl-1H-indazole
• CAS NO: 885518-82-1
• Molecular Formula: C₉H₇IN₂O₂
• Molecular Weight: 302.066
• Product Categories: Building Blocks;Indazole;Indazoles
• Mol File: 885518-82-1.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 421.4°C at 760 mmHg
• Flash Point: 208.6°C
• Appearance: /
• Density: 1.948g/cm³
• Vapor Pressure: 2.62E-07mmHg at 25°C
• Refractive Index: 1.72
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.47±0.40(Predicted)
• CAS DataBase Reference: 1H-INDAZOLE-6-CARBOXYLIC ACID,3-IODO-,METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDAZOLE-6-CARBOXYLIC ACID,3-IODO-,METHYL ESTER(885518-82-1)
• EPA Substance Registry System: 1H-INDAZOLE-6-CARBOXYLIC ACID,3-IODO-,METHYL ESTER(885518-82-1)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• WGK Germany: 3
• Hazardous Substances Data: 885518-82-1(Hazardous Substances Data)

Usage

General Description

1H-Indazole-6-carboxylic acid, 3-iodo-, methyl ester is a chemical compound with the molecular formula C9H7INO2. It is an ester form of 3-iodo-1H-indazole-6-carboxylic acid and is commonly used as a reagent in organic synthesis. 1H-INDAZOLE-6-CARBOXYLIC ACID,3-IODO-,METHYL ESTER is known for its potential applications in pharmaceutical and medicinal chemistry, particularly in the development of new drugs and biologically active molecules. Its unique structure and reactivity make it a valuable building block for the synthesis of various bioactive compounds and heterocyclic derivatives. Additionally, 1H-Indazole-6-carboxylic acid, 3-iodo-, methyl ester is also used in research and development projects focused on discovering novel pharmaceutical agents and investigating the biological activities of related chemical compounds.

InChI:InChI=1/C9H7IN2O2/c1-14-9(13)5-2-3-6-7(4-5)11-12-8(6)10/h2-4H,1H3,(H,11,12)

Upstream product

• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 704-91-6 1H-indazole-6-carboxylic acid 

Downstream Products

• 1561949-64-1 methyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)cyclohex-3-enecarboxylate 
• 1561949-61-8 1-(2-chloro-6-(trifluoromethyl)benzoyl)-3-iodo-N,N-dimethyl-1H-indazole-6-carboxamide 
• 1041205-25-7 methyl 3-iodo-1-methyl-1H-indazole-6-carboxylate 
• 1799420-87-3 1-(tert-butoxycarbonyl)-3-iodo-1H-indazole-6-carboxylic acid 
• 1086391-11-8 3-iodo-1H-indazole-6-carboxylic acid 

Relevant articles and documents

INHIBITORS OF ENL/AF9 YEATS

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS

The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.